Brown et al. tested off the shelf, healthy donor-derived, steroid-resistant IL-13Rα2-targeted CAR-T cells which were infused locally into the tumor via a Rickham catheter, in combination with intracranial administration of recombinant human IL-2 (aldesleukin) and systemic dexamethasone in a phase I trial in six patients with recurrent GBM. This evidence concerns the gene IL13RA2 and neoplasm.